Kilitch Drugs (India) Ltd

Kilitch Drugs (India) has recently adjusted its evaluation, showcasing an 18.33% growth in net sales for the quarter ending December 2024, reaching Rs 56.17 crore. The profit after tax also saw a significant rise of 44.8%, despite challenges in management efficiency and a low debt-to-equity ratio.

Kilitch Drugs (India) has announced its financial results for the quarter ending December 2024, showcasing strong growth in key metrics such as Profit Before Tax and net sales. However, rising interest expenses and declining cash reserves raise concerns about liquidity, while a decrease in the Debtors Turnover Ratio indicates slower receivable settlements.

Kilitch Drugs (India) has experienced a recent evaluation adjustment, reflecting its market position and financial metrics. The company reported significant profit growth and record net sales for Q2 FY24-25. However, concerns about management efficiency and a negative return over the past year have influenced this change.

Kilitch Drugs (India) has recently undergone an adjustment in its evaluation by MarketsMOJO, reflecting the company's mixed performance indicators. While it reported impressive growth in profit and net sales for Q2 FY24-25, challenges in management efficiency and a lack of investor confidence remain evident. The stock has been added to MarketsMOJO's list, highlighting its potential amidst ongoing concerns.

Kilitch Drugs (India) has reported a positive financial performance in the quarter ending September 2024, with growth in PBT and PAT, and the highest net sales in the last five quarters. However, the company's declining Operating Cash Flow and high reliance on non-business income are areas of concern for long-term sustainability.

Kilitch Drugs (India) has reported a significant decline in its financial performance for the quarter ending March 2024. The company's score has fallen from 2 to -22, with a decrease in PBT, PAT, and Net Sales. Interest costs have also risen, indicating increased borrowings. The company's operating profit margin has decreased, and its income from non-business activities is high. Investors are advised to exercise caution while considering this stock.

Kilitch Drugs (India) has been downgraded to a 'Sell' by MarketsMOJO due to poor management efficiency, low long-term growth, and a high debt-to-equity ratio. The stock is also trading at an expensive valuation and has low investor interest. Investors should carefully consider these factors before making any decisions regarding this microcap pharmaceutical company.

Kilitch Drugs (India) has been upgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio and mildly bullish trend. However, the company's management efficiency and long-term growth are areas of concern. Domestic mutual funds hold 0% of the stock, possibly due to its fair valuation and lack of interest in the company's business.

Kilitch Drugs (India), a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to poor management efficiency, low long-term growth, and high debt-to-equity ratio. Technical factors also indicate a potential downward trend. Despite some positives, caution is advised for investors.

Kilitch Drugs (India) has released its financial results for the quarter ended March 2024, with a 'Hold' call from MarketsMOJO. The company's performance has remained stable, with a flat score of 3. However, there are positive trends in PAT and PBT, indicating a promising near-term outlook.

Kilitch Drugs (India) has reported a flat performance in the quarter ending December 2023, with a significant decrease in profit before tax, net sales, and operating profit. The company's financial report also shows a decline in operating profit and profit before tax, along with concerns about debt and liquidity. Investors are advised to hold their stocks and monitor future reports closely.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high of Rs. 468.95 on February 8th. The stock has outperformed the sector by 1.77% and has shown a 7.55% increase in the past two days. With strong investor interest and positive market sentiment, the stock is currently trading higher than its moving averages and has shown an impressive growth of 216.66% in the past year. With a 'Hold' call from MarketsMOJO, Kilitch Drugs is a promising player in the pharmaceutical industry.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has reached an all-time high price of Rs.468.95 on February 8th, 2024. According to MarketsMOJO, the stock call for Kilitch Drugs (India) is 'Hold', indicating a stable performance. The stock has outperformed the sector by 4.43% today and is currently trading higher than its moving averages, showcasing its strong performance and potential in the market.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs. 463.4 on February 4th, 2024. Despite a 'Hold' rating from MarketsMOJO, the stock has outperformed the market and is currently trading above its moving averages, showcasing its strong performance and growth potential.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs. 463.4 on February 3rd, 2024. The company's stock is currently rated as 'Hold' by MarketsMOJO, but has outperformed the sector and market in the past year, showcasing its strong growth potential.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has reached a 52-week high and an all-time high of Rs. 463.4. The stock is currently rated as 'Hold' by MarketsMOJO and has underperformed the sector by -0.83%. However, it has shown a positive trend and outperformed the market in the past year, indicating potential for growth in the pharmaceutical industry.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs. 463.4 on February 2nd, 2024. The stock has been gaining for the past two days, with a 6.21% increase in returns. It has also outperformed the sector by 4.82% today, indicating a positive trend in the pharmaceutical industry. The stock is currently trading higher than its moving averages and has shown a significant increase of 191.29% in the past year. MarketsMOJO has given a 'Hold' call for the stock, reflecting a neutral stance.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high of Rs.455. It has consistently traded higher than its moving averages and outperformed the Sensex by 180.30%. MarketsMOJO has given a 'Hold' rating, indicating a steady outlook for the company.

Kilitch Drugs (India) Ltd, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs.455 on January 30th, 2024. The company's stock has outperformed the Sensex with a 178.04% increase in the past year and is currently trading higher than its moving averages, indicating a positive trend.